Ryan McDonald | Contributors

Novel Therapy Granted Priority Review By FDA for Treatment of Anal Cancer Subset

January 22, 2021

The priority review will focus on retifanlimab for the treatment of certain adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who did not tolerate platinum-based chemotherapy. Currently, according to Incyte, there are no approved treatments for this patient population.